Loading…
Orchestra BioMed Holdings, Inc. is projected to rise to $5.13 by 2027, a +30% move from its current price of $3.95. OBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.84 | $3.95 | $4.07 | +0.05% |
| May 30 | $3.80 | $3.95 | $4.12 | +0.09% |
| May 31 | $3.77 | $3.96 | $4.16 | +0.14% |
| Jun 1 | $3.74 | $3.96 | $4.19 | +0.19% |
| Jun 2 | $3.71 | $3.96 | $4.22 | +0.23% |
| Jun 3 | $3.69 | $3.96 | $4.25 | +0.28% |
| Jun 4 | $3.68 | $3.96 | $4.27 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.68 | $3.96 | $4.27 | +0.32% |
| Week 2 | $3.57 | $3.98 | $4.42 | +0.65% |
| Week 3 | $3.50 | $3.99 | $4.54 | +0.98% |
| Week 4 | $3.44 | $4.00 | $4.65 | +1.30% |
| Week 5 | $3.39 | $4.01 | $4.75 | +1.63% |
| Week 6 | $3.35 | $4.03 | $4.84 | +1.96% |
| Week 7 | $3.31 | $4.04 | $4.93 | +2.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Orchestra BioMed Holdings, Inc. is a healthcare company operating in the United States. It focuses on biomedical technologies and devices addressing cardiovascular and related conditions, with a portfolio of product candidates and therapies in development. The company was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Its flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, CNT-HF, and offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. The company has a collaboration agreement with Medtronic, Inc.
for AVIM therapy in pacemaker-indicated patients and a strategic collaboration with Terumo Corporation for Virtue SAB in coronary and peripheral vascular disease.
This description positions Orchestra BioMed as a diversified vascular and cardiac device company with ongoing partnerships and a focus on bioelectronic and therapeutic device platforms, anchored by its 2018 founding and New Hope, Pennsylvania headquarters.
OBIO is currently priced at $4.06 with a market cap of $243.12M and is listed with a rank of 3700. The near-term outlook is neutral for 2026, with a 2026 average price of $4.06, a range from $3.49 to $5.55, and a computed ROI of 0. The forecast progresses toward bullish sentiment in later years, with increasing average prices and ROIs: 2027 avg $5.37 (ROI 32.2), 2028 avg $6.13 (ROI 50.9), 2029 avg $6.82 (ROI 68.1), 2030 avg $7.19 (ROI 77.2).
The long horizon shows continued upside through 2040 and 2050, with 2040 avg $16.89 (ROI 316.1) and 2050 avg $27.16 (ROI 568.9).
This places OBIO on a path of growing price expectations and bullish sentiment beyond 2026, though the early year remains neutral and subject to market variability.
A major floor 18.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 15.9% above — a clean break opens room to run.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key OBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.01 | Sell | $3.99 | Sell |
| MA 10 | $3.99 | Sell | $4.00 | Sell |
| MA 20 | $3.99 | Sell | $4.03 | Sell |
| MA 50 | $4.21 | Sell | $4.12 | Sell |
| MA 100 | $4.21 | Sell | $4.13 | Sell |
| MA 200 | $3.86 | Buy | $4.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.83 | Neutral |
| Stoch RSI (14) | 62.12 | Neutral |
| CCI (20) | -37.39 | Neutral |
| Williams %R (14) | -41.03 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.23 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 58.97 | Neutral |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 58.77 | Neutral |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 4.03 | Sell |
| ADX (14) | 9.68 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture indicates a bullish tilt in the broader trend while the near term shows mixed signals. RSI(14) sits at 50, suggesting neutral momentum within the current range. The 50-day moving average is $4.23 and the 200-day moving average is $3.85, providing a supportive upward bias.
Key support is at $3.72 and resistance at $4.58, framing a near-term trading band. The 30-day range spans from a low of $3.33 to a high of $4.95, outlining the immediate price corridor in which OBIO might move.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.49 | $3.95 | $5.35 | 0% | Neutral | |
| $4.06 | $5.13 | $6.90 | +30% | Bullish | |
| $4.55 | $5.92 | $8.25 | +50% | Bullish | |
| $4.90 | $6.54 | $9.39 | +66% | Bullish | |
| $5.04 | $6.87 | $10.11 | +74% | Bullish | |
| $5.10 | $7.09 | $10.66 | +80% | Bullish | |
| $5.13 | $7.26 | $11.14 | +84% | Bullish | |
| $5.83 | $8.39 | $13.08 | +112% | Bullish | |
| $7.24 | $10.58 | $16.78 | +168% | Bullish | |
| $7.33 | $10.89 | $17.52 | +176% | Bullish | |
| $10.12 | $16.13 | $27.66 | +308% | Bullish | |
| $14.39 | $25.92 | $48.73 | +556% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.49 | $3.95 | $4.64 | +0.00% |
| June 2026 | $3.47 | $4.07 | $4.91 | +3.14% |
| July 2026 | $3.47 | $4.12 | $5.03 | +1.13% |
| August 2026 | $3.36 | $4.01 | $4.95 | -2.65% |
| September 2026 | $3.38 | $4.06 | $5.06 | +1.27% |
| October 2026 | $3.52 | $4.25 | $5.34 | +4.67% |
| November 2026 | $3.51 | $4.26 | $5.39 | +0.25% |
| December 2026 | $3.45 | $4.21 | $5.35 | -1.30% |
Click any year to see its month-by-month OBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect OBIO to range from $3.49 to $5.35 through 2026. The $3.95 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The OBIO price prediction for 2027 points to an average of $5.13 (low $4.06, high $6.90) — a potential gain of +30% on today's $3.95. Buyers look set to stay in control over this stretch.
In 2028, OBIO is projected to trade between $4.55 and $8.25, averaging $5.92 — a potential gain of +50% from today's $3.95. That is up +15% on the projected 2027 average. Momentum favours further upside here.
Orchestra BioMed Holdings, Inc.'s 2029 outlook centres on $6.54, within a $4.90 to $9.39 range. That is up +10% on the projected 2028 average. That marks a +66% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, OBIO could reach as high as $10.11, with a base case around $6.87 and support toward $5.04 — roughly +74% from $3.95. Momentum favours further upside here.
Expect OBIO to range from $5.10 to $10.66 through 2031. The $7.09 average target implies a +80% move from current prices. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The OBIO price prediction for 2032 points to an average of $7.26 (low $5.13, high $11.14) — a potential gain of +84% on today's $3.95. Momentum favours further upside here.
In 2033, OBIO is projected to trade between $5.83 and $13.08, averaging $8.39 — a potential gain of +112% from today's $3.95. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Orchestra BioMed Holdings, Inc.'s 2034 outlook centres on $10.58, within a $7.24 to $16.78 range. That is up +26% on the projected 2033 average. That marks a +168% change versus current levels. Momentum favours further upside here.
By 2035, OBIO could reach as high as $17.52, with a base case around $10.89 and support toward $7.33 — roughly +176% from $3.95. Buyers look set to stay in control over this stretch.
Expect OBIO to range from $10.12 to $27.66 through 2040. The $16.13 average target implies a +308% move from current prices. That is up +48% on the projected 2035 average. Momentum favours further upside here.
The OBIO price prediction for 2050 points to an average of $25.92 (low $14.39, high $48.73) — a potential gain of +556% on today's $3.95. Buyers look set to stay in control over this stretch.
Investing $1,000 in OBIO today (≈ 253.164557 OBIO) could be worth
$6,562.37
+$5,562.37 (+556%) by 2050 · US Dollar
Based on the average projected OBIO price of $25.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OBIOwould be worth at today's price.
$1,000 invested in OBIO on May 27, 2025 (≈ 354.609937 OBIO) would be worth
$1,400.71
+$400.71 (+40.1%) today · 1.40× · US Dollar
Based on a OBIO entry price of $2.82 vs. today's $3.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.98 | $992.46 | -0.8% |
| 1 month ago | $4.1 | $963.41 | -3.7% |
| 3 months ago | $4.33 | $912.24 | -8.8% |
| 6 months ago | $5.32 | $742.48 | -25.8% |
| 1 year ago | $2.82 | $1,400.71 | +40.1% |
| All time (5.0y) ago | $10.31 | $383.12 | -61.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OBIO forecast.
Our base-case forecast reaches $7.90 around 2033.
Implied market cap at $7.90: $473.06M
Longer-term projections show a multi-year ascent with rising averages and robust ROI. In 2030 the forecast shows an average price of $7.19 with a 77.2 ROI, within a bullish sentiment frame. The 2040 projection increases to an average of $16.89 with a 316.1 ROI, and the 2050 projection climbs to an average of $27.16 with a 568.9 ROI, both bullish.
The year-by-year path includes a 2027 average of $5.37 (ROI 32.2), 2028 average of $6.13 (ROI 50.9), 2029 average of $6.82 (ROI 68.1), 2031 average of $7.30 (ROI 79.8), 2032 average of $7.54 (ROI 85.7), and 2033 average of $8.82 (ROI 117.2). By 2034 the forecast shows $11.06 (ROI 172.4) and 2035 $11.41 (ROI 181). These figures imply sustained upside potential, tempered by the inherent uncertainty of healthcare device markets and regulatory dynamics.
Overall, the forecast outlines a clear bullish trajectory into the 2030s and beyond, with substantial upside in the 2040s and 2050s, but with risk and variability that could affect the realized outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.19 with ROI 77.2 and a bullish sentiment.
The long-range forecast is bullish, with positive averages and ROIs in 2027 onward (e.g., 2027 avg $5.37 with ROI 32.2; 2040 avg $16.89 with ROI 316.1; 2050 avg $27.16 with ROI 568.9), though 2026 is neutral and outcomes are not guaranteed.
Yes. The 2030 max forecast is $10.70, which exceeds $10.
The 30-day range is $3.33 to $4.95.
Current price is $4.06 and market cap is $243.12M.
Orchestra BioMed Holdings, Inc. Community Discussion
0Share your Orchestra BioMed Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.